Introduction
Breast cancer is one of the most common malignancies in the Western world, with one in 12 women developing the disease within their lifetime. Overexpression of the proto-oncogene ERBB2 (HER2/neu) is observed in 25-30% of all such cancers, and is an established adverse prognostic factor (Slamon et al., 1987 (Slamon et al., , 1989 Ross and Fletcher, 1999; Menard et al., 2001 ) yielding a median survival of 3 years, compared with 6-7 years when unassociated with ERBB2. Overexpression also correlates with tumor size, lymph node metastases, high nuclear grade, high percentage of S-phase cells, aneuploidy and estrogen receptor (ER) and progesterone receptor (PR) negativity (Ross and Fletcher, 1998) . ERBB2 overexpression may also predict resistance to both chemotherapy and endocrine therapy, although this remains controversial (Houston et al., 1999; Miles et al., 1999; Yu and Hung, 2000) . The ERBB2 receptor has become the first oncogene product to be targeted for breast cancer therapy, by the humanized anti-ERBB2 monoclonal antibody trastuzumab (Herceptin) (Baselga et al., 1996; Cobleigh et al., 1999; Slamon et al., 2001) .
There is much evidence to suggest that ERBB2 is not the only gene activated by amplification at 17q12-q21 in breast cancer (Tomasetto et al., 1995; Bieche et al., 1996; Kauraniemi et al., 2001) . Owing to the potential contribution of these other genes within the ERBB2 amplicon (17q12-q21) to breast tumorigenesis in vivo, it has been difficult to determine the precise role played by ERBB2-mediated signalling, and to establish the mechanisms by which anti-ERBB2 therapeutic agents exert their antiproliferative effects.
We have previously established a model of ERBB2 overexpression in conditionally immortalized human mammary luminal epithelial cells. Transfection of the HB4a human mammary epithelial cell line with ERBB2 cDNA resulted in two cell lines, C3.6 and C5.2, which showed 'moderate' and 'high' overexpression of ERBB2, respectively . These cells do not exhibit amplification at 17q12-q21, and thereby provide an opportunity to examine ERBB2-related signalling independent of the effects of other related coamplified genes.
Accordingly, we have investigated the transcriptional changes associated with ERBB2 overexpression in breast epithelial cells using cDNA microarrays employing 9930 cDNA clones representing approximately 6000 unique genes/ESTs. A total of 61 statistically significant differentially expressed genes (greater than 2.0-fold) associated with ERBB2 overexpression were identified. Their clinical relevance was demonstrated at the protein level by carrying out immunohistochemistry on a tissue array comprising 48 ERBB2-positive and 47 ERBB2-negative breast carcinomas.
Results

cDNA microarray analysis
Using the normalized data from our 9930 clone cDNA microarrays, gene lists were generated by SAM (version 1.12) for differentially expressed genes in the comparisons between C3.6 (moderately overexpressing ERBB2) and HB4a, C5.2 (highly overexpressing ERBB2) and HB4a, as well as between C3.6 and C5.2. Significance was assigned using a False Discovery Rate threshold of 1% in conjunction with a ratio threshold of 1.7. A set of 143 significantly upregulated and 140 significantly downregulated genes from the three comparisons was generated. In individual experiments, 61 genes were found to be differentially expressed in C3.6 compared to HB4a, 180 between C5.2 and HB4a and 91 between C5.2 and C3.6 (mean array ratios, SAM scores and s.d.'s for the list of 283 are provided in supplementary Table S2) .
By performing the three-way comparisons, the C5.2 versus C3.6 ratios can be predicted from the individual variant versus parental experiments. The actual : predicted plot is shown in Figure 1 , and gives a correlation coefficient of 0.968, allowing for an array-based control of the reproducibility of the data. For journal format brevity, a ratio threshold of 2.0 in the C5.2 versus HB4a comparison was used to produce a list of 36 upregulated and 25 downregulated unique genes, ranked according to ratio value (Table 1) . Of the 283 differentially expressed genes, 132 (46.7%) were found to be significant in both C5.2 and C3.6, including LGALS1, S100P, NDRG1, CDH3, EMP1, FN1, IGFBP3 and LGALS3.
We also examined a breast cancer cell line, BT474, using our cDNA microarrays. BT474 contains the 17q12-q21 amplicon, and allows for comparison with our ERBB2-transfected cell lines which do not. BT474 mRNA was reverse transcribed and hybridized with HB4a for direct comparison with the C3.6 and C5.2 data, in two replicated reverse-labelled experiments. In total, 274 statistically significant (SAM, 1% false discovery), differentially expressed (greater than 1.7-fold) genes are published in supplementary table S3.
Primary breast tumors 731 and 732 were also analysed by cDNA microarrays, hybridized against the normal luminal epithelial HB4a cells. This analysis generated lists of 187 and 91 differentially expressed genes, respectively, corresponding to a total of 152 unique genes (supplementary Table S3 ).
The Venn diagram in Figure 2 shows a summary of overlaps of differentially expressed genes between the ERBB2-transfected breast luminal epithelial cell line C5.2, the ERBB2-amplicon-containing breast cancer cell line BT474, and ERBB2-overexpressing invasive ductal breast carcinomas examined by cDNA microarrays. The only gene to segregate with ERBB2 (differential in all analyses) was IGFBP3. Four genes, including FN1, PTRF and TIP-1, overlapped between C3.6/C5.2 and BT474. None of the differentially expressed genes in the C5.2 and C3.6 experiments are found at the 17q12-q21 amplicon. Eight genes that were found to be differential through analysis of C3.6/C5.2 were also up-or downregulated in the tumor samples, but were not discovered in the BT474 breast cancer cell line. These include the upregulated genes LGALS1, CRIP1, VIM and PRDX2, and the downregulated genes RPL17, MYL9, ADORA3 and GTF3A. Upregulated genes are shown in red, downregulated in green. Array ratio figures in italics reach formal statistical significance (SAM, 1% false discovery rate) 
Confirmation of differential expression
For a subset of differentially expressed genes generated from the cDNA microarray experiments, RT-PCR analysis of cell line RNA was carried out to confirm the relative levels of expression in the cell lines. In all, 51 out of 56 genes (91%) analysed showed a pattern of transcript abundance consistent with the microarray data in the cell lines C3.6 and C5.2. Figure 3 shows representative gels for a subset of 16 upregulated genes 
Breast tumor tissue array
Where there were appropriate commercial antibodies available, relative protein levels of the differentially expressed mRNA levels associated with our expression profiling data were probed by immunohistochemistry on a breast tumor tissue array. As representative examples, antibodies to HSPB1 (HSP27), LGALS3, FN1, ERBB2, MYC and IGFBP3, were obtained and were analysed by immunohistochemistry on a tissue array containing 48 ERBB2-positive and 47 grade-matched ERBB2-negative invasive ductal breast carcinomas (Figure 4 ). Statistical analysis was carried out examining associations between antibody staining in the ERBB2-positive and -negative tumor groups ( Table S4 .
Discussion
The ERBB2 protein is overexpressed owing to gene amplification in 25-30% of invasive ductal breast carcinomas, and correlates with a poor clinical prognosis. However, comparatively little is known mechanistically about the exact role of ERBB2 in breast tumorigenesis, other than that directly attributable to its role as a member of the ERBB receptor tyrosine kinase family. Investigations into ERBB2 action provide a paradigm for how molecular analyses can lead to the development of a novel clinical therapy (trastuzumab, Herceptin) targeted against a single gene product. However, although a humanized antibody against the receptor (Herceptin) showed some clinical benefit to around 25% of patients with ERBB2-positive metastatic breast cancer (Pegram et al., 1998) , most were not helped. Since little is known about the more global effects of ERBB2 overexpression in breast cancer and how these may impact on attempts to antagonize ERBB2 activity, we have undertaken expression profiling of ERBB2 overexpressing cell lines derived from a conditionally immortalized human mammary luminal epithelial cells, as a longitudinal model of ERBB2 transformation. This analysis revealed a large number of genes consistently up-or downregulated coordinately with ERBB2 overexpression. Some of these are known to be associated with transformation and proliferation in breast and other tissues, while others represent novel markers of ERBB2 function. Examples of known coordinately upregulated genes include members of the S100 calcium-binding protein family (S100P, S100A4), which have been previously implicated in breast tumorigenesis (Guerreiro Da Silva et al., 2000; Mazzucchelli, 2002) and specifically related to ERBB2 status (Perou et al., 2000; Rudland et al., 2000; Sørlie et al., 2001 ). These were upregulated in our model system, and therefore provide a validation of the
HSP27 ERBB2
LGALS3 Figure 4 Tissue array containing 48 ERBB2-positive and 47 ERBB2-negative primary breast tumors. Immunohistochemical staining for ERBB2, HSP27 and LGALS3 (all same tumor core, HB049) is show (Hughes, 2001 ).
LGALS1 has been reported to act as an autocrine negative growth factor that regulates cell proliferation (Goldstone and Lavin, 1991; Baldini et al., 1993) and to bind oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation (Paz et al., 2001) . Interestingly, LGALS3 (galectin 3) was found to be significantly downregulated in our model, agreeing with published data (Andre et al., 1999) indicating a correlation of increased LGALS1 and reduced LGALS3 in breast carcinomas with metastatic propensity.
LGALS3 is thought to regulate many biological processes including cell adhesion, migration, cell growth, tumor progression, metastasis and apoptosis (Moon et al., 2001) . The mechanisms by which the galectins exert these effects remain largely unknown (Perillo et al., 1998) , and to our knowledge, this is the first report associating galectin up-or downregulation with ERBB2 expression in breast carcinomas and thus possibly contributing significantly to its impact on prognosis.
Other differentially expressed genes associated with cell-matrix interactions include matrix metalloproteinases, P4HA2 (proline 4-hydroxylase), FN1 (fibronectin 1) and CDH3 (p-cadherin). Silencing of fibronectin expression has been described as one of the key mechanisms underlying metastatic behavior in adenocarcinomas (Werbajh et al., 1998) , and has previously been reported to be crucial for ERBB2-induced invasive potentiation (Ignatoski et al., 2000) . P-cadherin, a calcium-dependent cell-cell adhesion glycoprotein, was also upregulated in erbB2-overexpressing cell lines and has been previously shown to correlate with poor prognosis in breast cancers (Peralta Soler et al., 1999; Gamallo et al., 2001) . One of the most significant overexpressed genes in our study was hypothetical protein PRO2605, which shows strong sequence similarity to the laminin receptor protein 1. High expression of laminin has also been previously identified as a marker of poor prognosis in breast cancer (De Iorio et al., 2001) .
One of the most significantly downregulated genes associated with ERBB2 overexpression was insulin-like growth factor binding protein 3 (IGFBP3). IGFBP3 is a major determinant of circulating levels of IGFs, which are potent mitogenic agents in breast cancer cells (Stoll, 1997) . Breast tumors are reported to show decreased levels of IGFBP3, and this correlates inversely with ER status (Rocha et al., 1996) . IGFBP3 has been purported to be a proapoptotic protein, regulated by blocking IGF-1R regulation of HIF1 activation of p53 (Shen and Glazer, 1998) . Loss of IGFBP3, and subsequent increased IGF-1R signalling, has been reported to play a role in resistance to trastuzumab (Herceptin) in vitro (Lu et al., 2001) , suggesting that strategies targeting these pathways may prevent or delay development of trastuzumab resistance in ERBB2-overexpressing breast tumors.
An intriguing aspect of our data involves MYC, a transcription factor whose amplification and overexpression correlates to metastasis and poor prognosis in breast cancer patients (Scorilas et al., 1999) . MYC was also found to be differentially expressed in our model system coordinately with ERBB2 expression. A recent report has shown that coamplification of MYC and ERBB2 is associated with a significant reduction in patient survival (Cuny et al., 2000) . As in addition to MYC itself, a number of other genes known to interact with MYC were also differentially expressed in our model system, for example, USF2, NMYC and the NMYC downstream regulated gene NDRG1 (Cap43), further implicating myc family member signalling in ERBB2-associated breast tumorigenesis. Other MYCassociated genes, epithelial membrane proteins 1 (EMP1, TMP, CL20) and 3 (EMP3, YMP) were also significantly upregulated in our model system. EMP1 and EMP3 are members of the PMP22/EMP/MP20 family of membrane glycoproteins, involved in squamous cell differentiation (Chen et al., 1997; Ben-Porath et al., 1998 Liehr et al., 1999) . Their precise functions in the breast are unknown but associations with cell proliferation and tumorigenesis have been proposed, and differential expression of EMP1 has been reported in gastric cancer (Hippo et al., 2001 ) and in estrogen-resistant MCF7ADR breast cancer cells (Schiemann et al., 1997) . Given its trans-membrane localization within epithelial cells, EMP1 (and possibly EMP3) represents novel and potentially useful targets for prognosis and targeting for therapy.
In summary, expression profiling of our model cell lines has revealed 61 genes that are significantly up-or downregulated by greater than 2.0-fold in response to ERBB2 overexpression in vitro, independent of other genes on the 17q12-q21 amplicon. We have attempted, by means of RT-PCR screening of breast tumor samples and immunohistochemistry on breast tumor tissue arrays, to demonstrate a potential clinical role for the up-or downregulation of some of these genes and their protein products. Further validation will involve both retrospective studies of tumor samples, and targeted inhibition in this in vitro model. It is hoped, therefore, that some of the genes identified in this study will provide new targets for the development of new treatment regimens to enhance the existing methods of abrogating ERBB2 activity in overexpressing breast cancers and thereby improving their efficacy and scope.
Materials and methods
Tissue culture and tumor preparations
The cell lines C5.2 and C3.6 were established by transfecting the normal mammary luminal epithelial cell line HB4a with ERBB2 cDNA derived from the BT474 breast cancer cell line . HB4a, C3.6 and C5.2 were cultured in RPMI-1640 with 10% (v/v) FCS, 5 mg/ml hydrocortisone, insulin, 2 mm glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin. Cell lines MCF-7, BT474 and SKBR3 were grown in Dulbecco's modified Eagle's medium supplemented with 10% FCS 100 IU/ml penicillin and 100 mg/ml streptomy-ERBB2-related gene expression using microarrays A Mackay et al cin. All cells were cultured in an atmosphere of 5% (v/v) carbon dioxide in a humidified incubator at 36.51C. Total RNAs were extracted from cultured cells by the guanadiniumphenyl chloroform extraction method (Chomczynski and Sacchi, 1987) .
Breast tumors were collected directly after surgical removal, flash frozen in liquid nitrogen prior to storage at À801C. To extract RNA, tumors were pulverized under liquid nitrogen and homogenized in a high-speed homogeniser (Ultra-Turrax) in guanadinium isothiocyanate prior to phenol chloroform extraction as above (Chomczynski and Sacchi, 1987) . Tumors 731 and 732 were obtained from Hospital do Cancer AC Camargo, Sao Paulo, Brazil, and RNA was prepared for cDNA microarray analysis.
cDNA microarray hybridizations
The cDNA microarrays used in this study were constructed at the Sanger Centre as part of the LICR/CRUK Microarray Consortium, containing 9930 sequence-validated cDNA clones representing approximately 6000 unique sequences. Information regarding clone set and array preparation can be obtained from http://www.sanger.ac.uk/Projects/Microarrays/. All annotation in published gene lists is derived from an Ensembl gene build based on the June 2002 NCBI 30 Golden Path assembly.
In each of the five experiments, RNA preparations from the C3.6, C5.2 and parental HB4a cell lines were each labelled separately with both Cy3 and Cy5 dyes and hybridized to microarrays in all combinations of cell line and dye (i.e. six hybridizations per experiment, 30 in total). RNA from the BT474 breast cancer cell line and two grade III invasive ductal breast carcinomas were hybridized in replicated reverselabelled experiments against RNA from HB4a cells as a reference.
Total RNA (25 mg) was used to prepare direct Cy3-and Cy5-labelled first-strand cDNA probes using a single-base anchored oligo dT 17 primer (Sigma-Genosys) and Superscript II reverse transcriptase (Invitrogen). The probes were purified using AutoSeq G-50 columns (Amersham), and Cy3-and Cy5-labelled probes were coprecipitated with 8 mg human Cot 1 DNA (Invitrogen) and 8 mg poly dA (Sigma). The pellets were resuspended in hybridization buffer (4 Â SSC, 5 Â Denhardt's solution, 50 mm Tris-HCl, pH 7.6, 0.1% sarkosyl, 40% formamide) and split across both arrays for hybridization at 471C overnight. The slides were washed in 2 Â SSC (once), 0.1 Â SSC, 0.1% SDS (four changes) and 0.1 Â SSC (once), and dried in a centrifuge before scanning. Fluorescent images of hybridized microarrays were captured using either the GenePix 4000 (Axon) dual color confocal laser scanner and GenePix software or a GSI Lumonics 4000 scanner and ScanArray software; data were recorded as paired 16-bit TIFF images. Images were quantitated and background subtracted using GSI Lumonics Quantarray 3.0 software. All raw fluorescence intensity data and microarray image files are deposited within the public repository for microarray-based gene expression data ArrayExpress ( www.ebi.ac.uk/arrayexpress), complying with minimun information about a microarray experiment (MIAME) and microarray gene expression database (MGED) group standards (Brazma et al., 2001) . The ArrayExpress accession number for this experiment is E-SNGR-8.
Image processing and data analysis
The background-corrected fluorescence intensity measurements from each experiment were log transformed (base 2) and plotted on an MA plot (Yang et al., 2002) , shown in supplementary Figure S1 . The interquartile range (IQR) of the average intensity (A) values for each hybridization was used as a quality measure. Lower IQR values correlate with higher average background, a higher proportion of flagged spots and imply a lower resolution of the expression measurements. The six hybridizations for each cell line comparison, which had the highest IQR values and which preserved balanced dye labeling, were selected for further analysis. More than half of the hybridizations used had IQR values greater than 1.0 and none selected were below 0.5. As some of the better hybridizations showed obvious dye bias, the log expression ratios were normalized using Lowess local regression as described by Yang et al. (2002) , using the implementation in the S-plus statistical analysis package (Insightful.com). The resulting sets of log ratios (i.e. six replicates per comparison) showed similar median absolute deviation (MAD) and were not normalized further. All flagged spots had values recorded as missing. For each cell line comparison, differentially expressed genes were identified by application of the statistical analysis of microarray (SAM, version 1.12) Excel add-in, one class analysis. A false discovery rate threshold of 1% in conjunction with a ratio threshold of 1.7 was used to define a set of significantly up-and downregulated genes from the three comparisons. The BT474 tumor-derived line and the tumor samples 731 and 732 each had four replicates (two fluor flip replicates). Normalized log ratios were derived by Lowess local regression (as above), but because of some variation in the MAD of the log ratios between the replicates, these were rescaled by use of the robust estimate of the scale factor used by Yang et al. (15) for print tip normalization. Differentially expressed genes were identified by application of SAM as above.
RT-PCR
Total RNA (10 mg) was reverse transcribed from an oligo-dT primer under conventional conditions (Superscript II, Invitrogen). The resulting reaction was diluted 10-fold in water and 2 ml was used as a template for PCR amplification. PCR was performed under standard conditions in 50 ml; 10 mm Tris pH 8.3, 50 mm KCl, 1.5 mm MgCl 2 , 200 mm dNTPs, 0.2 mm each primer (sense and antisense) and 1 U AmpliTaq polymerase (Applied Biosystems) with PCR cycles of 941C for 1 min, then 25-40 cycles of 941C for 30 s, 55-601C for 1 min and 721C for 1-2 min with a final cycle of 721C for 5 min. Products were resolved by standard agarose gel electrophoresis and visualized by ethidium bromide staining under UV light. Primer sequences are found in supplementary Table S1 .
Tissue array construction and immunohistochemistry
Breast tumors were selected from the archives of the Royal Marsden Hospital, London, UK with appropriate local Ethical Committee approval. A total of 48 ERBB2-positive and 47 grade-matched ERBB2-negative (as determined by routine immunohistochemistry) invasive ductal carcinomas were retrieved and reviewed by an experienced pathologist (SRL). The paraffin blocks were marked and punched with 0.6 mm 2 tumor cores taken from the donor blocks for inclusion in duplicate recipient tissue array blocks using a precision tissue array instrument (Beecher Instruments) (Kononen et al., 1998) .
Antibodies to differentially expressed genes were obtained commercially, where available, for tissue array profiling. All tissue array sections were dewaxed in xylene overnight, taken to ethanol (99.7-100% v/v) and blocked for endogenous peroxidase in methanol for 10 min. For FN1 and LGALS3, ERBB2-related gene expression using microarrays A Mackay et al each section was subjected to a high-temperature unmasking technique (2 min pressure cooking in citrate buffer, pH 6.0). Antigen unmasking was not necessary for HSP27. The sections were blocked in normal horse serum (2.5%, Vector Labs) for 20 min, and primary antibodies applied for 30 min (MYC, 1 : 150 (Vector Labs); IGFBP3, 1 : 20 (R&D Systems); FN1, 1 : 15 000 (Dako); LGALS3, 1 : 750 (Vector Labs); HSP27, 1 : 200 (Vector Labs)). All antibodies were diluted in Trisbuffered saline (TBS). The primary antibodies were rinsed off in 0.1% Tween 20 in TBS, developed using Vectastain Universal ABC kit (Vector Labs), and visualized with diaminobenzidine (DAB, Dako).
